Inactive Instrument

Bunuru Corporation Ltd Stock Australian S.E.

Equities

AU000000BUN2

End-of-day quote Australian S.E.
- AUD - Intraday chart for Bunuru Corporation Ltd
Invitrocue Limited Announces Resignation of Directors CI
Invitrocue Limited Announces Invivocue Pte Ltd Completes Development of its Ace-2 Humanized Immune Mice Platform CI
Invitrocue Limited Enters into Partnership with Pangaea Oncology SA CI
Invitrocue Limited Announces the Appointment of Chow Yee Koh as an Executive Director of the Company as Replacement of Geoffrey Thomas CI
Invitrocue Limited, Invitrocue Pte Ltd Sign Binding Memorandum of Understanding with Felipe Eduardo De Almeida E Silva for the Establishment of a Joint Venture Company Called Invitrocue Brazil CI
Invitrocue Limited Announces Joint Venture with ChinaLink Limited CI
Invitrocue Limited announced that it expects to receive $10.25 million in funding CI
INVITROCUE (HONG KONG) LTD announced that it expects to receive $1 million in funding from Invitrocue Limited and other investor CI
Invitrocue Limited Announces the Cessation of Kit Wei Lui as Director, Effective from 15 October 2019 CI
Invitrocue Limited Announces the Cessation of Hanry Yu as Director, Effective from 15 October 2019 CI
Invitrocue Limited Announces Cancellation of General Meeting CI
Hanry Yu, Kit Wei Lui and Ee Ting Ng Tender Their Resignation as Directors of Invitrocue Limited CI
Declaration of Voting Results by Invitrocue Limited CI
Invitrocue Limited Reports Earnings Results for the Full Year Ended June 30, 2019 CI
Invitrocue Limited announced that it has received $0.75 million in funding CI
More news
Managers TitleAgeSince
Founder 58 11-12-31
Chief Operating Officer - 16-04-30
Director/Board Member - 18-02-06
Members of the board TitleAgeSince
Founder 58 11-12-31
Comptroller/Controller/Auditor - 15-05-17
Director/Board Member - 18-02-06
More insiders
Invitrocue Limited is engaged in research and experimental development on biotechnology, life and medical science. The Company offers a three dimension (3D) cell-based scaffolding technology, which mimics a human for Tropical Diseases to investigate the lifecycle of Plasmodium cynomolgi (monkey malaria) and helps in evaluating new drug targets to malaria infection using in vitro hepatocyte culture systems. It is engaged in developing non-small cell lung cancer organoids and for drug testing programs using approved drugs. It is also engaged in range of activities, including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging, while providing access to industry networks. It also offers an in vitro screening of experimental drug compounds for anti-leishmanial activity. It intends to develop an in vitro 3D perfused liver model to expedite and facilitate new application notes in infectious liver diseases.
Sector
-
More about the company